TY - JOUR
T1 - Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995-2012
AU - Salek, M.S.
AU - Jung, S.
AU - Brincat-Ruffini, L.A.
AU - MacFarlane, L.
AU - Lewis-Jones, M.S.
AU - Basra, M.K.A.
AU - Finlay, A.Y.
PY - 2013
Y1 - 2013
N2 - The Children's Dermatology Life Quality Index (CDLQI) is a widely used questionnaire to measure the quality of life of children aged from 4 to 16 years. The purpose of this review is to summarize all published data regarding the clinical experience of the CDLQI and its psychometric properties as a single reference source for potential users. A literature search was carried out to identify all articles describing the use of the CDLQI from 1995 to November 2012. One hundred and six articles were identified, with four excluded. The CDLQI has been used in 28 countries in 102 clinical studies and is available in 44 languages, including six cultural adaptations; a cartoon version is available in 10 languages. It has been used in 14 skin conditions and used in the assessment of 11 topical drugs, nine systemic drugs, 13 therapeutic interventions and two epidemiological and other studies. There is evidence of high internal consistency, test-retest reliability, responsiveness to change, and significant correlation with other subjective and objective measures. Rasch analysis has not been carried out and more information is needed concerning minimal clinically important difference; these are areas requiring further study.
What's already known about this topic?
The quality of life of children can be impaired by skin disease.
The CDLQI is a simple 10-item questionnaire to measure the impact of skin diseases on children's quality of life.
The CDLQI is available in two versions, text only and text with cartoons.
What does this study add?
The CDLQI has been used in 102 research studies in 28 countries.
There is detailed documentation of 14 skin diseases in which there is major impairment of quality of life in children.
Previously scattered validation data have been identified and brought together.
The CDLQI has strong validation characteristics including high internal consistency, test-retest reliability and responsiveness to change.
Some aspects of validation requiring further study have been identified.
AB - The Children's Dermatology Life Quality Index (CDLQI) is a widely used questionnaire to measure the quality of life of children aged from 4 to 16 years. The purpose of this review is to summarize all published data regarding the clinical experience of the CDLQI and its psychometric properties as a single reference source for potential users. A literature search was carried out to identify all articles describing the use of the CDLQI from 1995 to November 2012. One hundred and six articles were identified, with four excluded. The CDLQI has been used in 28 countries in 102 clinical studies and is available in 44 languages, including six cultural adaptations; a cartoon version is available in 10 languages. It has been used in 14 skin conditions and used in the assessment of 11 topical drugs, nine systemic drugs, 13 therapeutic interventions and two epidemiological and other studies. There is evidence of high internal consistency, test-retest reliability, responsiveness to change, and significant correlation with other subjective and objective measures. Rasch analysis has not been carried out and more information is needed concerning minimal clinically important difference; these are areas requiring further study.
What's already known about this topic?
The quality of life of children can be impaired by skin disease.
The CDLQI is a simple 10-item questionnaire to measure the impact of skin diseases on children's quality of life.
The CDLQI is available in two versions, text only and text with cartoons.
What does this study add?
The CDLQI has been used in 102 research studies in 28 countries.
There is detailed documentation of 14 skin diseases in which there is major impairment of quality of life in children.
Previously scattered validation data have been identified and brought together.
The CDLQI has strong validation characteristics including high internal consistency, test-retest reliability and responsiveness to change.
Some aspects of validation requiring further study have been identified.
UR - http://www.scopus.com/inward/record.url?scp=84885597920&partnerID=8YFLogxK
U2 - 10.1111/bjd.12437
DO - 10.1111/bjd.12437
M3 - Article
C2 - 23679682
AN - SCOPUS:84885597920
SN - 0007-0963
VL - 169
SP - 734
EP - 759
JO - British Journal of Dermatology
JF - British Journal of Dermatology
IS - 4
ER -